newsfilter
← Latest News
PR Newswire·

Brii Biosciences Provides Corporate Updates and Reports 2023 Interim Results

First patient dosed in a PEG-IFN-α controlled BRII-835 + PEG-IFN-α combination Phase 2 study for HBV functional cure First of several studies to investigate the potential of BRII-179 in enriching patients with strong